Chronic myelomonocytic leukemia (CMML) is a rare blood cancer of older adults, and its life expectancy varies widely: some people live many years with few symptoms, while others with higher-risk disease have a much shorter outlook. Survival depends mainly on blast count, blood counts, specific gene mutations and overall fitness, and doctors use prognostic scoring systems to estimate it. Management ranges from monitoring and supportive care to hypomethylating drugs, and stem cell transplantation remains the only potential cure.
In my work with hematologic malignancies, CMML is one of the conditions where patients most want a clear answer about the future. This article explains how that answer is reached, along with what causes the disease and how it is treated.
What Is Chronic Myelomonocytic Leukemia?
Chronic myelomonocytic leukemia is a clonal disorder of the blood-forming stem cells in the bone marrow. It has features of two disease families at once: the abnormal, inefficient cell production of a myelodysplastic syndrome and the overproduction typical of a myeloproliferative neoplasm. For that reason, it is classified as an overlap condition.
The hallmark is a persistently raised number of monocytes, a type of white blood cell. Understanding the normal composition and function of bone marrow helps explain why CMML can cause both too many of some cells and too few of others.
Despite the similar names, CMML is a different disease from chronic myelogenous leukemia, which is driven by the BCR-ABL1 fusion gene and treated very differently. It also differs from acute myelomonocytic leukemia, a form of acute myeloid leukemia (AML) in which blasts make up 20% or more of cells.
Causes and Risk Factors
In most patients, CMML arises sporadically, without an identifiable trigger. It results from acquired mutations in a marrow stem cell, which accumulate with age.
- Age: the disease mainly affects people over 60, and it is more common in men.
- Gene mutations: mutations in TET2, SRSF2 and ASXL1 are among the most frequent. RAS-pathway mutations (NRAS, KRAS, CBL) are common in the proliferative form.
- Prior cancer treatment: a minority of cases follow chemotherapy or radiation for an earlier cancer.
- Environmental exposures: exposure to agents such as benzene or high-dose radiation may contribute in some patients.
CMML is not inherited in the usual sense, and it is not contagious.
Symptoms and Diagnosis
Many people are diagnosed after a routine blood test shows a high monocyte count. When symptoms occur, they usually reflect low blood counts, an enlarged spleen or the inflammatory effects of the disease.
- Fatigue and breathlessness from anemia
- Infections from poorly functioning white cells
- Bruising or bleeding from low platelets
- Fullness or discomfort under the left ribs from an enlarged spleen
- Fever, night sweats and weight loss
Diagnostic workup
Diagnosis combines blood, marrow and genetic findings. The core requirement is persistent monocytosis, with monocytes making up at least 10% of white cells. The absolute threshold was 1 × 10^9/L in earlier WHO criteria and was lowered to 0.5 × 10^9/L in the 2022 WHO classification when other supportive features are present.
A bone marrow aspirate and biopsy look for dysplasia, count blasts and assess cellularity. Cytogenetics and a molecular panel identify mutations. Importantly, doctors must exclude other causes of monocytosis, such as infection or inflammation, and rule out CML and other myeloproliferative neoplasms by testing for BCR-ABL1 and related rearrangements.
| Category | Definition | Why it matters |
|---|---|---|
| CMML-1 | Blasts under 5% in blood and under 10% in marrow | Generally a better outlook |
| CMML-2 | Blasts 5–19% in blood or 10–19% in marrow | Higher risk of progression |
| Myelodysplastic type (MD-CMML) | White cell count below 13 × 10^9/L | Behaves more like MDS; cytopenias dominate |
| Myeloproliferative type (MP-CMML) | White cell count 13 × 10^9/L or higher | More splenomegaly and systemic symptoms; often a less favorable course |
CMML Life Expectancy: What Determines Prognosis
There is no single life expectancy for CMML. Median survival is usually counted in years rather than decades, but the range is wide. Someone with low blasts, near-normal counts and a favorable mutation profile may live well for many years, while higher-risk disease can progress over months to a few years.
The main factors that influence outlook include:
- Blast percentage (CMML-2 carries higher risk than CMML-1)
- White cell count and the proliferative subtype
- Red cell transfusion dependence
- Chromosome abnormalities, grouped into low, intermediate and high risk
- Mutations, particularly ASXL1, which is associated with a worse outlook
- Age, fitness and other medical conditions
Doctors combine these in validated tools such as the CMML-specific Prognostic Scoring System (CPSS), its molecular version CPSS-Mol, and the Mayo Molecular Model. These place patients into risk groups that guide treatment decisions. A minority of patients eventually progress to AML, which carries a poorer prognosis.
In my practice, I encourage patients to see these estimates as group averages. Individual courses often differ, and repeated assessments over time are more informative than any single number at diagnosis.
Management Strategies
Treatment is tailored to risk, symptoms and fitness. There is no one-size-fits-all approach.
Watchful waiting and supportive care
Lower-risk patients without troublesome symptoms are often monitored with regular blood counts. Supportive care includes red cell or platelet transfusions, treatment of infections and, in some patients with anemia, erythropoiesis-stimulating agents.
Hypomethylating agents
Azacitidine and decitabine are the main disease-modifying drugs for higher-risk CMML. They can improve blood counts and symptoms and may slow progression, though they are not curative.
Cytoreduction
In proliferative CMML with very high white counts or a painful spleen, hydroxyurea is often used to control counts and symptoms.
Stem cell transplantation
Allogeneic hematopoietic stem cell transplantation is the only treatment that can cure CMML. Because most patients are older or have other health problems, it is suitable for only a minority, usually fitter patients with higher-risk disease.
Clinical trials
Research is exploring agents directed at specific pathways and mutations, including JAK inhibitors and IDH inhibitors. Joining a trial can give access to newer options and is worth discussing with your hematologist. For related conditions, see our leukemia guide.
Key Takeaways
- CMML is a rare overlap disorder with features of both MDS and myeloproliferative neoplasms, defined by persistent monocytosis.
- Life expectancy varies widely and is best estimated using scoring systems such as CPSS and CPSS-Mol.
- Blast count, transfusion needs, chromosomes and mutations such as ASXL1 are key prognostic factors.
- Management ranges from monitoring to hypomethylating agents; transplantation is the only cure.
Frequently Asked Questions
Is CMML a type of leukemia or MDS?
It is both, in a sense. CMML is classified as a myelodysplastic/myeloproliferative overlap neoplasm and is called a leukemia because of its monocyte-rich blood picture. Its behavior sits between chronic and acute leukemia.
Can CMML turn into acute leukemia?
Yes, a minority of patients progress to acute myeloid leukemia, defined by blasts reaching 20% or more. The risk is higher with CMML-2, adverse chromosomes and certain mutations. Regular monitoring helps detect progression early.
Can CMML be cured?
Allogeneic stem cell transplantation is the only potentially curative treatment. Other therapies, including hypomethylating agents, aim to control the disease and improve quality of life rather than cure it.
Does everyone with CMML need treatment right away?
No. Many people with lower-risk disease and stable counts are simply monitored. Treatment starts when symptoms, falling counts or higher-risk features make it worthwhile.
